

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: DINGIVAN *et al.*

Confirmation No.: 7180

Application No.: 10/091,236

Group Art Unit: 1644

Filed: March 4, 2002

Examiner: GAMBEL, Phillip

For: METHODS OF PREVENTING OR
TREATING INFLAMMATORY OR
AUTOIMMUNE DISORDERS BY
ADMINISTERING INTEGRIN
ALPHABETA3 ANTAGONISTS IN
COMBINATION WITH OTHER
PROPHYLACTIC OR THERAPEUTIC
AGENTS

Attorney Docket No.: VI300US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form(s) PTO/SB/08, a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.98.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final office action on the merits but before payment of the issue fee.


In compliance with 37 C.F.R. §1.97(e) Applicants submit that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, no item of information contained in the information disclosure statement was known to be material to patentability to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any fees, which may be required regarding this application under 37 C.F.R. §§ 1.17(p) to Deposit Account No. 500479.

Respectfully submitted,

By:


Janet Martineau
Registration No. 46,903
Attorney for Applicants

Date: July 3, 2007
MEDIMMUNE, INC.
Customer Number: 365777
Telephone: (301) 398-4532
Facsimile: (301) 398-9306